BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 20807812)

  • 1. PTEN loss accelerates KrasG12D-induced pancreatic cancer development.
    Hill R; Calvopina JH; Kim C; Wang Y; Dawson DW; Donahue TR; Dry S; Wu H
    Cancer Res; 2010 Sep; 70(18):7114-24. PubMed ID: 20807812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
    He P; Yang JW; Yang VW; Bialkowska AB
    Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras
    Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B
    Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANGPTL4 accelerates KRAS
    Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
    Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell intrinsic role of COX-2 in pancreatic cancer development.
    Hill R; Li Y; Tran LM; Dry S; Calvopina JH; Garcia A; Kim C; Wang Y; Donahue TR; Herschman HR; Wu H
    Mol Cancer Ther; 2012 Oct; 11(10):2127-37. PubMed ID: 22784710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases.
    Liou GY; Byrd CJ; Storz P; Messex JK
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis.
    Costamagna A; Natalini D; Camacho Leal MDP; Simoni M; Gozzelino L; Cappello P; Novelli F; Ambrogio C; Defilippi P; Turco E; Giovannetti E; Hirsch E; Cabodi S; Martini M
    Gastroenterology; 2022 Apr; 162(4):1242-1255.e11. PubMed ID: 34922945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.
    Zhang Z; Li H; Deng Y; Schuck K; Raulefs S; Maeritz N; Yu Y; Hechler T; Pahl A; Fernández-Sáiz V; Wan Y; Wang G; Engleitner T; Öllinger R; Rad R; Reichert M; Diakopoulos KN; Weber V; Li J; Shen S; Zou X; Kleeff J; Mihaljevic A; Michalski CW; Algül H; Friess H; Kong B
    Gastroenterology; 2021 Nov; 161(5):1601-1614.e23. PubMed ID: 34303658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
    Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
    Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
    Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV
    Int J Cancer; 2012 Oct; 131(8):1951-62. PubMed ID: 22287227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
    Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.